Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2014. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons, specifically detailing changes in their interests in the Company's Ordinary Shares and American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director share allocations.
Material Changes
On December 31, 2013, Non-Executive Directors were provisionally allocated awards over Ordinary Shares and ADSs through the annual reinvestment of dividends paid throughout 2013. These allocations were calculated using an average price of £16.07 per Ordinary Share and $53.17 per ADS. The Company and Directors were informed of these allocations on January 2, 2014.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Non-Executive Directors received provisional share awards on December 31, 2013, based on 2013 dividend reinvestment.
- The valuation used for allocations was £16.07 per Ordinary Share and $53.17 per ADS.
- Specific allocation amounts were disclosed for ten Non-Executive Directors, including Sir Christopher Gent (4,354.409 Ordinary Shares) and Sir Robert Wilson (1,485.756 Ordinary Shares).
- The report was signed by Simon Bicknell on January 3, 2014.